Idelalisib + Ofatumumab as First Line Therapy for Patients with CLL

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Idelalisib + Ofatumumab as First Line Therapy for Patients with CLL at ASH 2015